Sartorius Stedim Biotech stock rises 2% and targets resistance at €197.90

The stock recovers above its moving averages and approaches its resistance at €197.90

Sartorius Stedim Biotech closes at €193.90, up 2.05% from the previous day (€190). The stock ranks among the strongest gainers of the SBF 120, in an index that gains 0.65% at close. This advance allows the stock to consolidate its position above its three moving averages: it trades 1.57% above the 20-day MA at €190.90, and over 6% above the 50-day and 200-day MAs, respectively at €182.59 and €182.29.

The RSI at 53 remains in neutral territory, with no overbought signal, which leaves technical room before the resistance identified at €197.90. This zone had already constituted a ceiling during the attempted breakout in early September, when the stock had declined nearly 3% after breaking above €195 in late August. The support at €172.90 remains far below the current price, offering comfortable cushion on technical levels.

A gain of 10.5% over three months supported by financial targets confirmed in July

Over one month, the stock advances 4.53%, and 10.55% over three months, a sign of a sustained upward trend since summer. This movement follows the publication of first-half 2026 results on July 22, when the company had confirmed its annual targets: revenue targeted at approximately €3.15 billion and EBITDA expected at nearly €989 million. The breakthrough of the €195 resistance in late August had accompanied this momentum, although the stock subsequently fell below this threshold in early September. According to the consensus of analysts tracked, the stock trades at approximately 38.8 times expected earnings for the current fiscal year and 32.3 times those of the following fiscal year, a demanding valuation that reflects sector expectations for a recovery in biopharmaceutical equipment. The next technical milestone remains the test of the €197.90 resistance, a threshold whose sustained breakout would be the next confirmation of the trend.